Loading
ProAgio is a protein drug from ProDa BioTech that targets an integrin receptor found on tumour blood vessels and the support cells around tumours. It is in an early trial with gemcitabine in triple-negative breast cancer that has spread.
ProAgio is developed by ProDa BioTech and described in the registry as an anti-alpha-v-beta-3 integrin cytotoxin. The phase 1/2 trial NCT06460298 tests rising doses and then an expansion dose of ProAgio with gemcitabine in metastatic triple-negative breast cancer, with 51 participants planned.
Described in its ClinicalTrials.gov record as an anti-alpha-v-beta-3 integrin cytotoxin.
1.ProAgio's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ProAgio" OR ABSTRACT:"ProAgio") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ProAgio, not a curated reading list.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/